A partnership between Alliance and Opus Genetics aims to advance gene therapy development and seeks IND filing with the FDA.
1 report, 1 independent
Updated Jul 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A partnership between Alliance and Opus Genetics aims to advance gene therapy development and seeks IND filing with the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Opus Genetics plans to submit an application to the FDA.Sub-event
The partnership aims to advance gene therapy development and seeks IND filing with the FDA.1 source
Keep exploring
The entities involved
Related events
- The FDA reversed its decision regarding a gene therapy application from uniQure N.V.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- DHHS defined boundaries for gene-editing products on October 29, 2026.
- A network focused on cell and gene therapies is expanding to include sites in Northern California, involving the CA Institute for Regenerative Medicine and the FDA.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
Coverage
Newest first; wire copies grouped- GlobeNewswireOpus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH1